Table 8.
Scenario analyses: cost-effectiveness
| Discontinuation analysis | OAB-5D analysis | |||
|---|---|---|---|---|
| FDC tablet solifenacin 6 mg + TOCAS | Tolterodine + tamsulosin | FDC tablet solifenacin 6 mg + TOCAS | Tolterodine + tamsulosin | |
| Total costs* (£) | 860 | 942 | 860 | 959 |
| Difference | – | −82 | – | −99 |
| QALYs* | 0.839 | 0.838 | 0.835 | 0.831 |
| Difference | – | 0.0006 | – | 0.004 |
| ICER*‡ | – | Dominates (−£133,473) | – | Dominates (−£26,143) |
*Per patient at 1 year.
‡FDC tablet solifenacin 6 mg + TOCAS versus tolterodine + tamsulosin.
FDC, fixed-dose combination; ICER, incremental cost effectiveness ratio; QALY, quality of life adjusted years; TOCAS, oral controlled absorption system (OCAS™) formulation of tamsulosin.